There were no apparent safety concerns in patients with low baseline LDL cholesterol levels (< 3 mmol/ l), in whom average LDL cholesterol levels during the trial were 1.8 mmol/ l in the simvastatin-treated group and 2.7 mmol/ l in the group receiving placebo.